-- Earnings Flash (AVEO) AVEO PHARMACEUTICALS Reports Q1 Revenue $20.9M, vs. Street Est of $20.8M
7:01AM ET 5/05/2022 MT Newswires...
Quotes Snapshot > AVEO
Aveo Pharmaceuticals Inc AVEO:NASDAQ
Last Price$4.15NASDAQ Previous Close - Last Trade as of 4:00PM ET 5/18/22
Today's Change-0.10(2.35%)
Bid (Size)$2.60 (1)
Ask (Size)$4.17 (33)
Day Low / High$4.03 - 4.24
Volume171.5 K
Read more news Recent News
--JonesTrading Initiates AVEO Pharmaceuticals With Buy Rating, $12 Price Target
2:25PM ET 3/14/2022 MT Newswires(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...
AVEO Pharmaceuticals Net Loss Narrows, Revenue Increases in Q4
7:28AM ET 3/14/2022 MT NewswiresAVEO Pharmaceuticals (AVEO) reported a Q4 net loss Monday of $0.21 per share, compared with a loss of $0.44 a year earlier. Analysts polled by Capital IQ...
-- Earnings Flash (AVEO) AVEO PHARMACEUTICALS Posts Q4 Revenue $17.6M, vs. Street Est of $18.3M
7:03AM ET 3/14/2022 MT Newswires...
View all Commentary and Analysis
AVEO Pharmaceuticals' (AVEO) CEO Michael Bailey on Q1 2022 Results - Earnings Call Transcript
5:57PM ET 5/05/2022 Seeking AlphaAVEO Pharmaceuticals Inc's (AVEO) CEO Michael Bailey on Q4 2021 Results - Earnings Call Transcript
1:22PM ET 3/14/2022 Seeking AlphaAVEO Pharmaceuticals: Finally Ready To Reboot
10:25PM ET 3/08/2022 Seeking AlphaBiotech 101 Lecture 3: Looking At Major Biotech Catalysts
3:23PM ET 3/08/2022 Seeking AlphaCompany Profile
Business DescriptionAVEO Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the advancement of therapeutics for oncology, and other areas of unmet medical need. Its product candidates include Tivozanib, Ficlatuzmab, AV-203, AV-380 and AV-353. The company was founded by Ronald A. DePinho, Lynda Chin, and Kenneth E. Weg on October 19, 2001 and is headquartered in Cambridge, MA. View company web site for more details
| Address | 30 Winter Street Boston, Massachusetts 02108 |
| Phone | +1.617.400.0101 |
| Number of Employees | 17 |
| Recent SEC Filing | 05/13/2022 3/A |
| President, Chief Executive Officer & Director | Michael P. Bailey |
| Chief Operating Officer | Jebediah Ledell |
| Chief Financial Officer | Erick J. Lucera |
| Vice President-Information Technology | Matthew Coulter |
Company Highlights
| Price Open | $4.15 |
| Previous Close | $4.15 |
| 52 Week Range | $3.06 - 7.59 |
| Market Capitalization | $143.1 M |
| Shares Outstanding | 34.5 M |
| Sector | Health Technology |
| Industry | Pharmaceuticals: Major | Next Earnings Announcement | 08/04/2022 |
Options Summary
| Call Open Interest (1d)* |  |
| Put Open Interest (1d)* | |
| Call Volume (1d)* | |
| Put Volume (1d)* | |
| Put Call Open Interest Ratio (1d)* | |
| Put Call Volume Ratio (1d)* | |
| * Data delayed by up to 15 minutes |
View all fundamentalsFundamentals
| Price / Earnings | N/A |
| Earnings per Share | -$1.26 |
| Beta vs. S&P 500 | N/A |
| Revenue | $5.4 M |
| Net Profit Margin | -67.57% |
| Return on Equity | -85.29% |
Analyst Ratings as of 03/14/2022
| Buy | |
| Overweight | |
| Hold | |
| Underweight | |
| Sell | |
Consensus Recommendation | |